Parker Institute for Cancer Immunotherapy Appoints Bob Purcell as New Chief Communications Officer

Parker Institute for Cancer Immunotherapy Welcomes Bob Purcell as Chief Communications Officer

The Parker Institute for Cancer Immunotherapy (PICI) recently celebrated a significant milestone with the announcement of Bob Purcell as its new Chief Communications Officer. This development comes as PICI enters its tenth year of operation, poised to enhance its mission to transform cancer treatment into a realm where all cancers can become curable.

Bob Purcell brings with him 25 years of robust experience in corporate and product communications, particularly within the realms of biotechnology, pharmaceuticals, diagnostics, and healthcare technology. His vast knowledge will play a crucial role in amplifying PICI's efforts in innovation and fostering collaborative research in cancer immunotherapy, ultimately focusing on improving patient outcomes.

In his position, Purcell will oversee a variety of communications functions, from managing internal and external communications to directing media relations and developing digital and social media strategies. His expertise in steering corporate messaging is expected to bolster PICI's influence and visibility, showcasing the significant impact of its scientific endeavors and the partnerships it cultivates.

Purcell expressed enthusiasm about joining PICI, stating, "The Parker Institute for Cancer Immunotherapy is advancing some of the most innovative cancer immunotherapy research in the world. I'm excited to join the organization and help communicate the impact of its scientific discoveries, foster collaboration, and support its mission to bring transformative therapies to patients."

His background includes a notable tenure as Head of Communications and Events at Verily, a subsidiary of Alphabet, where he pioneered communications strategies that supported healthcare innovations. Furthermore, he has spent over a decade in high-level communications roles at Genentech and Roche, enhancing external communications for Genentech's pharmaceutical and diagnostic divisions.

Dr. Karen E. Knudsen, CEO of PICI, commented on Purcell’s appointment, noting his deep understanding of strategic communications in the biopharma and life sciences sectors. She remarked, "Bob brings a strong understanding of how to effectively communicate complex science and drive meaningful engagement with key stakeholders."

The PICI, known for its innovative approach in cancer treatment, was established in 2016 through the vision of Sean Parker. As a 501c3 nonprofit entity, it aims to advance the next generation of cancer therapies by expediting the development of breakthrough immune treatments. PICI collaborates with the country's foremost cancer centers to fuel high-risk and high-reward science, sharing resources, data, and goals to enhance the overall effectiveness of cancer research initiatives.

Distinctively, PICI goes beyond mere discovery by actively facilitating the progress of promising innovations into clinical testing, company formation, and commercialization. This model has enabled them to support over 1,000 investigators and foster a portfolio comprising 17 biotech ventures with a remarkable $4 billion in capital raised.

With Bob Purcell at the helm of communications, PICI is set to strengthen its narrative, advancing both its vision and mission to drive breakthroughs that will ensure access to curative cancer therapies for patients. Through its unique integration of scientific brilliance and entrepreneurial spirit, PICI continues to redefine how we think about and develop cancer cures. For more details about PICI's groundbreaking work, you can visit their official website at parkerici.org.